114753-52-5

Basic information

• Product Name: 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside
• Synonyms: 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside;2-Amino-2',3'-dideoxy-3'-azidoadenosine;2-Amino-3'-azido-2',3'-dideoxyadenosine;2,6-diaMino-9-(3-azido-2,3-dideoxy-beta-D-erythro-pentofuranosyl)purine
• CAS NO: 114753-52-5
• Molecular Formula: C10H13N9O2
• Molecular Weight: 291.26932
• Mol File: 114753-52-5.mol

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: g/cm³
• CAS DataBase Reference: 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside(114753-52-5)
• EPA Substance Registry System: 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside(114753-52-5)

Safety Data

• Hazardous Substances Data: 114753-52-5(Hazardous Substances Data)

Upstream product

• 34097-37-5 2,6-bisacetamidopurine 
• 30516-87-1 3'-azido-2',3'-deoxythymidine 
• 2096-10-8 adenosine-2-amine 
• 121513-03-9 (2R,3R,5R)-5-(2,6-Diamino-purin-9-yl)-2-[(4-methoxy-phenyl)-diphenyl-methoxymethyl]-tetrahydro-furan-3-ol 
• 121231-93-4 2,6-diamino-9-(<2'-O-(p-tosyl)sulfonyl>-β-D-ribofuranosyl)purine 
• 116002-29-0 2,6-diamino-9-(2'-deoxy-β-D-threo-pentafuranosyl)purine 
• 121231-94-5 2,6-diamino-9-(2-deoxy-3-O-methanesulfonyl-β-D-threo-pentofuranosyl)purine 
• 121513-04-0 9-{(2R,4S,5S)-4-Azido-5-[(4-methoxy-phenyl)-diphenyl-methoxymethyl]-tetrahydro-furan-2-yl}-9H-purine-2,6-diamine 

Relevant articles and documents

Synthesis and evaluation of 3′-azido-2′,3′-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus

Based on the promising drug resistance profile and potent anti-HIV activity of β-d-3′-azido-2′,3′-dideoxyguanosine, a series of purine modified nucleosides were synthesized by a chemical transglycosylation reaction and evaluated for their antiviral activity, cytotoxicity, and intracellular metabolism. Among the synthesized compounds, several show potent and selective anti-HIV activity in primary lymphocytes.

3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS

The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, and HBV, in human patients or other animal hosts. The compounds are 3'-azido-2',3'-dideoxy purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 and HBV.

Nucleic acid related compounds. 57. Synthesis, X-ray crystal structure, lipophilic partition properties, and antiretroviral activities of anomeric 3'-azido-2',3'-dideoxy-2,6-diaminopurine ribosides

Trimethylsilyl triflate-catalyzed transfer glycosylation of 2,6-diacetamidopurine (2) with 3'-azido-3'-deoxythymidine (AZT, 1) as donor followed by deprotection gave 2,6-diamino-9-(3-azido-2,3-dideoxy-α- and -β-D-erythro-pentofuranosyl)purines (3 and 4) i